Abstract
Temsirolimus (Torisel; Wyeth) is an inhibitor of the kinase mTOR (mammalian target of rapamycin). It was approved by the US FDA for the treatment of advanced renal cell carcinoma in May 2007.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
Journal of Experimental & Clinical Cancer Research Open Access 12 March 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cohen, H. T. & McGovern, F. J. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477–2490 (2005).
Garcia, J. A. & Rini, B. I. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin. 57, 112–125 (2007).
Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Rev. Drug Discov. 5, 835–844 (2006).
Atkins, M. B. et al. Sunitinib maleate. Nature Rev. Drug Discov. 5, 279–280 (2006).
Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003).
Faivre, S., Kroemer, G. & Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nature Rev. Drug Discov. 5, 671–688 (2006).
Skotnicki, J. S., Leone, C. L. & Smith, A. L. Design, synthesis, and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779. Clin. Cancer Res. 7, S3749–S3750 (2001).
Atkins, M. B. et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909–918 (2004).
Food and Drug Administration. FDA labelling information [online], (2007).
Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).
Motzer, R. J. et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
Bukowski, R. M. et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). J. Clin. Oncol. 24 (Suppl. 1), 4523 (2006).
Raymond, E. et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin. Oncol. 22, 2336–2347 (2004).
Dutcher, J. P. et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J. Clin. Oncol. 25, (Suppl. 1) 5033 (2007).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
B. R. has received research funding from Wyeth and is a paid consultant for Wyeth.
Rights and permissions
About this article
Cite this article
Rini, B., Kar, S. & Kirkpatrick, P. Temsirolimus. Nat Rev Drug Discov 6, 599–600 (2007). https://doi.org/10.1038/nrd2382
Issue Date:
DOI: https://doi.org/10.1038/nrd2382
This article is cited by
-
A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
Journal of Experimental & Clinical Cancer Research (2019)
-
Oncogenic protein interfaces: small molecules, big challenges
Nature Reviews Cancer (2014)
-
New agents in renal cell carcinoma
Targeted Oncology (2014)
-
Importance of microbial natural products and the need to revitalize their discovery
Journal of Industrial Microbiology and Biotechnology (2014)
-
Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer
Breast Cancer Research and Treatment (2014)
